Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Medulloblastoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H1 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape. Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 3 and 13 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Medulloblastoma - Overview Medulloblastoma - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Medulloblastoma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Medulloblastoma - Companies Involved in Therapeutics Development Bayer AG Bristol-Myers Squibb Company DelMar Pharmaceuticals Inc Ignyta Inc IMPACT Therapeutics Inc Lipocure Ltd MacroGenics Inc NewLink Genetics Corp Novogen Ltd Ono Pharmaceutical Co Ltd Progenics Pharmaceuticals Inc Stemline Therapeutics Inc ThromboGenics NV VBI Vaccines Inc Medulloblastoma - Drug Profiles (topotecan hydrochloride + vincristine sulfate) - Drug Profile Product Description Mechanism Of Action R&D Progress Bispecific Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile Product Description Mechanism Of Action R&D Progress Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress dianhydrogalactitol - Drug Profile Product Description Mechanism Of Action R&D Progress Edotreotide Labeled Yttrium 90 - Drug Profile Product Description Mechanism Of Action R&D Progress IMP-5471 - Drug Profile Product Description Mechanism Of Action R&D Progress indoximod - Drug Profile Product Description Mechanism Of Action R&D Progress ipilimumab + nivolumab - Drug Profile Product Description Mechanism Of Action R&D Progress irinotecan hydrochloride + TBio-02 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-5 - Drug Profile Product Description Mechanism Of Action R&D Progress nifurtimox - Drug Profile Product Description Mechanism Of Action R&D Progress nifurtimox SR - Drug Profile Product Description Mechanism Of Action R&D Progress nivolumab - Drug Profile R&D Progress Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile Product Description Mechanism Of Action R&D Progress p28 - Drug Profile Product Description Mechanism Of Action R&D Progress pyrvinium pamoate - Drug Profile Product Description Mechanism Of Action R&D Progress SL-301 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile Product Description Mechanism Of Action R&D Progress taladegib - Drug Profile Product Description Mechanism Of Action R&D Progress THR-317 - Drug Profile Product Description Mechanism Of Action R&D Progress Trilexium - Drug Profile Product Description Mechanism Of Action R&D Progress VBI-1901 - Drug Profile Product Description Mechanism Of Action R&D Progress VIMO-001 - Drug Profile Product Description Mechanism Of Action R&D Progress VMY-1103 - Drug Profile Product Description Mechanism Of Action R&D Progress Medulloblastoma - Dormant Projects Medulloblastoma - Product Development Milestones Featured News & Press Releases Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Medulloblastoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Medulloblastoma - Pipeline by Bayer AG, H1 2017 Medulloblastoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017 Medulloblastoma - Pipeline by Ignyta Inc, H1 2017 Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H1 2017 Medulloblastoma - Pipeline by Lipocure Ltd, H1 2017 Medulloblastoma - Pipeline by MacroGenics Inc, H1 2017 Medulloblastoma - Pipeline by NewLink Genetics Corp, H1 2017 Medulloblastoma - Pipeline by Novogen Ltd, H1 2017 Medulloblastoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017 Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H1 2017 Medulloblastoma - Pipeline by ThromboGenics NV, H1 2017 Medulloblastoma - Pipeline by VBI Vaccines Inc, H1 2017 Medulloblastoma - Dormant Projects, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
